Search Result

Results for "

AD diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (5) Adrenergic Receptor (1) Amyloid-β (34) Apoptosis (10) Autophagy (2) Bacterial (4) Beta-secretase (13) Calcium Channel (2) Carbonic Anhydrase (3) Casein Kinase (1) Caspase (1) CCR (1) CDK (3) Cholinesterase (ChE) (63) COX (1) Dopamine Transporter (3) E1/E2/E3 Enzyme (2) Endogenous Metabolite (11) ERK (1) Glucocorticoid Receptor (2) GLUT (1) GSK-3 (7) HDAC (1) Histamine Receptor (3) Histone Methyltransferase (1) HIV (1) HSP (1) iGluR (1) Interleukin Related (4) IRAK (1) Isotope-Labeled Compounds (3) JNK (3) Keap1-Nrf2 (3) mAChR (2) MAGL (1) MicroRNA (1) Microtubule/Tubulin (5) Mitochondrial Metabolism (2) MMP (1) Monoamine Oxidase (13) mTOR (1) nAChR (5) Neuropeptide Y Receptor (2) NF-κB (4) NO Synthase (1) NOD-like Receptor (NLR) (2) Nuclear Factor of activated T Cells (NFAT) (1) p62 (2) Parasite (1) Phosphodiesterase (PDE) (3) Phospholipase (3) PI3K (1) PPAR (1) Prostaglandin Receptor (1) PROTACs (1) Proteasome (2) RIP kinase (1) Sodium Channel (1) Tau Protein (9) TNF Receptor (1) Trk Receptor (1) Wnt (2) α-synuclein (2) β-catenin (2) γ-secretase (4)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Endocrinology (12) Infection (4) Inflammation/Immunology (26) Metabolic Disease (3) Neurological Disease (179)

By Targets:

11β-HSD (2)

5-HT Receptor (5)

Adrenergic Receptor (1)

Amyloid-β (34)

Apoptosis (10)

Autophagy (2)

Bacterial (4)

Beta-secretase (13)

Calcium Channel (2)

Carbonic Anhydrase (3)

Casein Kinase (1)

Caspase (1)

CCR (1)

CDK (3)

Cholinesterase (ChE) (63)

COX (1)

Dopamine Transporter (3)

E1/E2/E3 Enzyme (2)

Endogenous Metabolite (11)

ERK (1)

Glucocorticoid Receptor (2)

GLUT (1)

GSK-3 (7)

HDAC (1)

Histamine Receptor (3)

Histone Methyltransferase (1)

HIV (1)

HSP (1)

iGluR (1)

Interleukin Related (4)

IRAK (1)

Isotope-Labeled Compounds (3)

JNK (3)

Keap1-Nrf2 (3)

mAChR (2)

MAGL (1)

MicroRNA (1)

Microtubule/Tubulin (5)

Mitochondrial Metabolism (2)

MMP (1)

Monoamine Oxidase (13)

mTOR (1)

nAChR (5)

Neuropeptide Y Receptor (2)

NF-κB (4)

NO Synthase (1)

NOD-like Receptor (NLR) (2)

Nuclear Factor of activated T Cells (NFAT) (1)

p62 (2)

Parasite (1)

Phosphodiesterase (PDE) (3)

Phospholipase (3)

PI3K (1)

PPAR (1)

Prostaglandin Receptor (1)

PROTACs (1)

Proteasome (2)

RIP kinase (1)

Sodium Channel (1)

Tau Protein (9)

TNF Receptor (1)

Trk Receptor (1)

Wnt (2)

α-synuclein (2)

β-catenin (2)

γ-secretase (4)

By Research Areas:

Cancer (9)

Cardiovascular Disease (3)

Endocrinology (12)

Infection (4)

Inflammation/Immunology (26)

Metabolic Disease (3)

Neurological Disease (179)

195

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14679

GSK3β inhibitor II

GSK-3 Neurological Disease

GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .

GSK3β inhibitor II	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .

HY-109055

Elenbecestat E2609	Beta-secretase	Neurological Disease
Elenbecestat (E2609) is a potent, orally bioavailable and CNS-penetrant BACE-1 inhibitor. Elenbecestat has the potential for Alzheimer's disease (AD) research .

HY-106000

GSK239512	Histamine Receptor	Neurological Disease
GSK239512 is a potent and brain penetrated H₃ receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) .

HY-144753

AChE/BChE-IN-2	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-2 (Compound 13b) is a potent inhibitor of AChE/BChE (AChE IC50 = 0.96 ± 0.14 µM, BChE IC50 = 1.23 ± 0.23 µM). AChE/BChE-IN-2 has the potential for the research of AD diseases .

HY-151405

Z164597606	Cholinesterase (ChE)	Neurological Disease
Z164597606 is a selective BChE inhibitor (IC₅₀: 1.3 and 1.7 μM for eqBChE and hBChE). Z164597606 forms a π-π stacking interaction with the amino acid Trp82 of hBChE. Z164597606 can be used for the research of Alzheimer’s disease (AD) .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC₅₀ of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-153189

TrkB-IN-1	Trk Receptor	Neurological Disease
TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties. TrkB-IN-1 reverses the cognitive defects in an AD mouse model and can be used for alzheimer’s disease research .

HY-105321

PBT 1033 PBT 2	Bacterial	Neurological Disease
PBT 1033 (PBT 2) is an orally active copper/zinc ionophore. PBT 1033 restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .

HY-N0702

Tenuifolin	Beta-secretase Cholinesterase (ChE)	Neurological Disease
Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).

HY-151368

AChE/BChE-IN-10	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-10 (Compound 7b) is a potent dual AChE and BChE inhibitor with IC₅₀ values of 0.176, and 0.47 μM, respectively. AChE/BChE-IN-10 shows good blood brain barrier permeability. AChE/BChE-IN-10 can inhibit Aβ-aggregation and be used in Alzheimer’s disease (AD) research .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3781

(Met(O)35)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .

HY-19369

L-685458 3 Publications Verification L-685,458	γ-secretase Apoptosis	Neurological Disease Cancer
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC₅₀ of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC₅₀s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .

HY-151386

BChE-IN-13	Cholinesterase (ChE)	Neurological Disease
BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .

HY-152113

AChE/BChE/MAO-B-IN-3	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, is a potent MAO-B inhibitor with an IC₅₀ of 0.0359 μM for human MAO-B. AChE/BChE/MAO-B-IN-3 is a potent AChE and BChE enzyme inhibitor, with IC₅₀s of 0.0473 μM and 0.0782 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-3 shows significant antioxidant activity and has the potential for Alzheimer's disease (AD) research .

HY-137315

TML-6	Amyloid-β NF-κB mTOR Keap1-Nrf2	Neurological Disease
TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research .

HY-152114

AChE/BChE/MAO-B-IN-4	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, is a potent MAO-B inhibitor with an IC₅₀ of 0.0393 μM for human MAO-B. AChE/BChE/MAO-B-IN-4 is a potent AChE and BChE enzyme inhibitor, with IC₅₀s of 0.0458 μM and 0.075 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-4 shows significant antioxidant activity and prevent β-amyloid plaque aggregation. AChE/BChE/MAO-B-IN-4 has the potential for Alzheimer's disease (AD) research .

HY-147859

BChE-IN-8	Amyloid-β	Neurological Disease
BChE-IN-8 (compound 20) is an orally active, potent and BBB-penetrated BChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.15 nM (eqBChE, equine serum BChE) and 45.2 nM (hBChE), respectively. High stability of BChE-IN-8 contributes to significantly improved blood concentration and tissue exposure. BChE-IN-8 can exert neuro-protecting and cognition improving properties through multiple modulations, including cholinergic system, Aβ aggregation, neuropeptide levels. BChE-IN-8 can be used for Alzheimer's disease (AD) research .

HY-149090

AChE/BuChE/MAO-B-IN-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent AChE/BuChE inhibitor and showed good blood brain barrier (BBB) permeability in vitro with an IC₅₀ value of 5.3 μM, 12.4 μM, 1.9±0.08 μM, for AChE, BuChE, huMAO-B, respectively. AChE/BuChE/MAO-B-IN-2 (compound 4b) can inhibit excess AChE/BuChE in Alzheimer's disease (AD) brain. AChE/BuChE/MAO-B-IN-2 (compound 4b) can be used in anti-Alzheimer's research .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC₅₀ values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-160481

MG-1102	Tau Protein MicroRNA	Neurological Disease
MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC₅₀s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a K_d of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD) .

HY-147720A

γ-Secretase modulator 11 hydrochloride	γ-secretase	Neurological Disease
γ-Secretase modulator 11 hydrochloride (compound 1o) is a potent and orally active γ-secretase modulator with an IC₅₀ of 0.029 µM. γ-Secretase modulator 11 hydrochloride induces a robust reduction in brain Aβ42 levels. γ-Secretase modulator 11 hydrochloride rescues cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has the potential for the research of alzheimer's disease .

HY-157527

hAChE-IN-7	Cholinesterase (ChE) Beta-secretase	Neurological Disease
hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC₅₀=69.8 nM) and hBuChE (IC₅₀=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC₅₀=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .

HY-141660

BSc3094

Tau Protein Neurological Disease

BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) .

BSc3094	Tau Protein	Neurological Disease
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) .

HY-11013

ZSET1446 ST-101	Calcium Channel nAChR	Neurological Disease Cancer
ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.

HY-149246

Aβ-IN-6	Amyloid-β Keap1-Nrf2	Neurological Disease Inflammation/Immunology
Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research .

HY-135006A

Octahydroaminoacridine	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine can be used for Alzheimer's disease (AD) research .

HY-P0198A

Neuropeptide Y (human,rat,mouse) (TFA)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-156585

CNS-11

Tau Protein Neurological Disease

CNS-11 is a compoud that disaggregates tau fibrils. CNS-11 can be used for Alzheimer's disease (AD) research .
HY-P0198

Neuropeptide Y (human,rat,mouse)

Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

CNS-11	Tau Protein	Neurological Disease
CNS-11 is a compoud that disaggregates tau fibrils. CNS-11 can be used for Alzheimer's disease (AD) research .

Neuropeptide Y (human,rat,mouse)
Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-135006

Octahydroaminoacridine succinate	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine succinate, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine succinate can be used for Alzheimer's disease (AD) research .

HY-162138

BChE-IN-23	Cholinesterase (ChE)	Neurological Disease
BChE-IN-23 (compound 2a) is a BChE inhibitor with an IC₅₀ value of 21 nM. BChE-IN-23 can be used in Alzheimer's disease (AD) research .

HY-144446

BuChE-IN-1	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-1 (Compound 23) is a potent inhibitor of butyrylcholinesterase (BuChE). Butyrylcholinesterase (BuChE) is recently regarded as a biomarker in progressed Alzheimer’s disease (AD). BuChE-IN-1 shows low cytotoxicity and high blood brain barrier (BBB) permeability. BuChE-IN-1 is a promising BuChE inhibitor for the research of AD .

HY-146068

AEP-IN-1	Others	Neurological Disease
AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC₅₀ of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .

HY-P1046

β-Amyloid (1-15) Amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-114234A

TAK-070 Free base	Beta-secretase	Neurological Disease
TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC₅₀: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-153183

Lp-PLA2-IN-12	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .

HY-113366

Prostaglandin J2 PGJ2	Prostaglandin Receptor Endogenous Metabolite	Neurological Disease
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-50682

Azeliragon 5+ Cited Publications TTP488; PF-04494700	Amyloid-β	Neurological Disease
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-17388

(±)-Huperzine A 1 Publications Verification	Cholinesterase (ChE)	Neurological Disease
(±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).

HY-112636

Astrophloxine	Amyloid-β	Others
Astrophloxine is a fluorescent imaging probe capable of targeting antiparallel dimers. Astrophloxine can be used to detect aggregated Aβ in brain tissue and cerebrospinal fluid samples of Alzheimer's disease (AD) mice .

HY-P99163

Tilavonemab ABBV-8E12; C2N-8E12	Microtubule/Tubulin	Neurological Disease
Tilavonemab (ABBV-8E12) is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease .

HY-P99164

Zagotenemab LY33003560	Microtubule/Tubulin	Neurological Disease
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library

1374 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1374 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L028

CNS-Penetrant Compound Library

856 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 856 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L086

Neurodegenerative Disease-related Compound Library

2228 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2228 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L134

Anti-Aging Natural Product Library

191 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 191 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L010

MAPK Compound Library

510 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 510 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

HY-L037

Antioxidant Compound Library

1482 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 1482 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

HY-L068

Flavonoids Library

511 compounds

Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc.

MCE offers a unique collection of 511 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.

Cat. No.	Product Name	Target	Research Area

HY-P1389

Neuropeptide S (human)	Peptides	Neurological Disease
Neuropeptide S human, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human can be used for Alzheimer's disease (AD) research .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is a potent degrader of cerebral amyloid-beta (Abeta). Abeta deposition is associatied with the Alzheimer disease (AD), due to its related toxicity linked to its beta-sheet conformation and/or aggregation. β-Sheet Breaker Peptide iAβ5 reproducibly induces in vivo disassembly of fibrillar amyloid deposits. Thus, β-Sheet Breaker Peptide iAβ5 prevents and/or reverses neuronal shrinkage caused by Abeta, and reduces the extent of interleukin-1beta positive microglia-like cells that surround the Abeta deposits. β-Sheet Breaker Peptide iAβ5 reduces the size and/or number of cerebral amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 labeled by hydrophobic benzyl alcohol (HBA) tag, can be used for quantitative assay by showing vivid blue color under acidic conditions .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P1389A

Neuropeptide S (human) (TFA)	Peptides	Neurological Disease
Neuropeptide S human TFA, a neuropeptide, is a potent cognate neuropeptide S receptor (NPSR) agonist. Neuropeptide S human TFA can be used for Alzheimer's disease (AD) research .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3781

(Met(O)35)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .

HY-P2473

Neurogranin (48-76), human	Peptides	Neurological Disease
Neurogranin (48-76), human is a dominant endogenous peptide in Alzheimer's disease (AD) brain tissue. Neurogranin (48-76) is a potential biomarker for synaptic function in AD .

HY-P0198A

Neuropeptide Y (human,rat,mouse) (TFA)	Neuropeptide Y Receptor	Neurological Disease Endocrinology
Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

HY-P1046

β-Amyloid (1-15) Amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P1466

β-Amyloid (1-16) Amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1468

β-Amyloid (1-28) Amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P3528

GPR	Caspase Apoptosis	Neurological Disease
GPR is a three amino acid peptide. GPR can rescue cultured rat hippocampal neurons from Aβ-induced neuronal death by inhibiting caspase-3/p53 dependent apoptosis. GPR can be used for the research of Alzheimer's disease (AD).

HY-P0198B

[D-Arg25]-Neuropeptide Y (human)	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease
[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY) is a Y₁ receptor selective agonist. Neuropeptide Y (human) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity .

HY-P10037

β Amyloid(17-28) human	Amyloid-β	Neurological Disease
β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD) .

HY-P3780

Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P1387

β-Amyloid (1-40) (rat) 1 Publications Verification	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca ²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .

HY-P4899

RE(EDANS)EVNLDAEFK(DABCYL)R	Beta-secretase	Neurological Disease
RE (EDANS) EVNLDAEFK (DABCYL) R is an EDANS and DABCYL double-labeled peptide，serves as a fluorescent substrate for BACE1(Em=360nm，Ex=528nm). RE (EDANS) EVNLDAEFK (DABCYL) R can be used for BACE1 activity measurement and the enzyme activity level is directly proportional to the fluorescence reaction .

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P4882

(Pyr3)-Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P4882A

(Pyr3)-Amyloid β-Protein (3-42) (TFA)	Amyloid-β	Neurological Disease
(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .

HY-P0175

740 Y-P 125+ Cited Publications 740YPDGFR; PDGFR 740Y-P	PI3K Autophagy	Cancer
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .

Cat. No.	Product Name	Target	Research Area

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .

HY-P99163

Tilavonemab ABBV-8E12; C2N-8E12	Microtubule/Tubulin	Neurological Disease
Tilavonemab (ABBV-8E12) is a humanised anti-tau antibody that binds amino acids 25-30 near the N-terminal end of the tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates and reduces brain atrophy. Tilavonemab can be used in the study of Alzheimer's disease .

HY-P99164

Zagotenemab LY33003560	Microtubule/Tubulin	Neurological Disease
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Inhibitory Antibodies	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

HY-P99648

Gosuranemab BMS-986168; IPN007; BIIB092	Tau Protein	Neurological Disease
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab is a bispecific and humanizedized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD) .

HY-P99673

Itepekimab REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0702

Tenuifolin	Triterpenes Structural Classification Terpenoids Source classification Polygalaceae Plants Polygala tenuifolia Willd.	Beta-secretase Cholinesterase (ChE)
Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).

HY-17388

(±)-Huperzine A 1 Publications Verification	Structural Classification Terpenoids Huperziaceae Sesquiterpenes Source classification Huperzia serrata Plants	Cholinesterase (ChE)
(±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).

HY-113366

Prostaglandin J2 PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-N10487

Bleformin A	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
Bleformin A is a potent BChE inhibitor with an IC₅₀ value of 5.2 μM. Bleformin A is a nature product that could be isolated from Bletilla striata. Bleformin A can be used for research of Alzheimer's disease (AD) .

HY-N10488

BChE-IN-11	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
BChE-IN-11 (compound 10) is a potent, selective and non-competitive BChE (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-125125

Danshenxinkun D	Quinones Structural Classification Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Phenanthrenequinones	Others
Danshenxinkun D is an anti-Alzheimer's disease (AD) candidate. Danshenxinkun D can significantly reverse the expression of PSEN1 and DRD2 mRNA in H₂O₂ treated PC12 cells. Danshenxinkun D can be used in the study of anti-Alzheimer's disease product candidate [1].

HY-N10490

Blestrin D	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
Blestrin D is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-N7887

Cassiaside	Seeds of Cassia tora Linn. other families Leguminosae Source classification Phenols Polyphenols Plants	Beta-secretase
Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against BACE1 (IC₅₀=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity .

HY-N0710

alpha-Cyperone 2 Publications Verification α-Cyperone; (+)-α-Cyperone	Structural Classification other families Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite
alpha-Cyperone (α-Cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1, resulting in reduction of inflammation, which would be highly beneficial for treatment of inflammatory diseases such as AD.

HY-N10489

BChE-IN-12	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀ value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Bletilla striata (Thunb. ex Murray) Rchb. f. Classification of Application Fields Neurological Disease Orchidaceae Source classification Phenols Polyphenols Plants Disease Research Fields	Cholinesterase (ChE)
BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀ value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-N12581

Kuwanon U	Structural Classification Flavonoids Flavonones Source classification Morus alba L. Plants Moraceae	Cholinesterase (ChE)
Kuwanon U is a potent cholinesterase inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-N0611

alpha-Boswellic acid α-Boswellic acid	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Boswellia serrata Plants Burseraceae Inflammation/Immunology Disease Research Fields	Others
alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .

HY-N3383

Ligustroside Ligstroside	Monophenols Iridoids Oleaceae Ligustrum japonicum Thunb. Terpenoids Source classification Phenols Plants	Mitochondrial Metabolism
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

HY-N11641

Methyl ganoderate A acetonide	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	Cholinesterase (ChE)
Methyl ganoderate A acetonide, a lanostane triterpene, is a natural product that could be isolated from the fruiting bodies of Ganoderma lucidum. Methyl ganoderate A acetonide is a potent AChE inhibitor with an IC₅₀ value of 18.35 μM. Methyl ganoderate A acetonide can be used in research of Alzheimer’s disease (AD) .

HY-113354

Anserine 1 Publications Verification	Microorganisms Immune System Disorder Ketones, Aldehydes, Acids Source classification Disease markers Nervous System Disorder Endogenous metabolite	Endogenous Metabolite
Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-N4027

Hydrangenol 8-O-glucoside Hydrangenol 8-O-β-D-glucopyranoside	Structural Classification Source classification Hydrangeaceae Coumarins Phenylpropanoids Plants	Cholinesterase (ChE)
Hydrangenol 8-O-glucoside (Hydrangenol 8-O-β-D-glucopyranoside) can be isolated from Hydrangea macrophyllu. Hydrangenol 8-O-glucoside is an AChE inhibitor (IC₅₀: 22.66 μM). Hydrangenol 8-O-glucoside inhibits passive cutaneous anaphylaxis (PCA) reaction .

HY-N10701

AChE/BChE-IN-11	Structural Classification Oleaceae Syringa oblata Lindl. Source classification Plants Saccharides Monosaccharides	Cholinesterase (ChE)
AChE/BChE-IN-11 (compound 1) is a potent is a dual AChE and BChE inhibitor with IC₅₀ values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research .

HY-N2807

Acanthoside B	Monophenols Cistanche salsa (C. A. Mey.) G. Beck Source classification Lignans Phenols Orobanchaceae Phenylpropanoids Plants	Others
Acanthoside B is a potential bioactive lignan with anti-inflammatory and anti-amnesic activities. Acanthoside B can be used for alzheimer's disease and lung inflammation research

HY-A0009

Galanthamine hydrobromide 10+ Cited Publications Galantamine hydrobromide	Structural Classification Alkaloids Other Alkaloids Source classification Plants Amaryllidaceae	Cholinesterase (ChE) nAChR
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-N0812

Timosaponin BII Prototimosaponin A III	Structural Classification Liliaceae Neurological Disease Classification of Application Fields Source classification Anemarrhena asphodeloides Bunge Plants Inflammation/Immunology Disease Research Fields Steroids	Amyloid-β
Timosaponin BII (Prototimosaponin A III) is a steroid saponin found in the rhizomes of Anemarrhena asphodeloides. Timosaponin BII has neuronal protective, anti-inflammatory and antioxidant activities .

HY-116753

(-)Clausenamide	Clausena lansium (Lour.) Skeels Source classification Rutaceae Plants	Amyloid-β Tau Protein
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-107577

Gedunin	Infection Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent Hsp90 inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-N0028

Forsythiaside A 1 Publications Verification	Structural Classification Classification of Application Fields Oleaceae Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plants Forsythia suspensa (Thunb.) Vahl Inflammation/Immunology Disease Research Fields	Others
Forsythiaside A is an orally active phenylethanoid glycoside isolated from the dried fruits of Forsythia suspensa. Forsythiaside A is also an inhibitor of COX-2 and has anti-inflammatory, antioxidant and neuroprotective effects. Forsythiaside A prevents neuroinflammation and apoptosis caused by Aβ_25-35 damage and may be used in Alzheimer's disease (AD) research. Forsythiaside A also activates the Nrf2/HO-1 signaling pathway and inhibits OVA-induced asthma in mice .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	Structural Classification Alkaloids Source classification Plants Amaryllidaceae	nAChR Cholinesterase (ChE)
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-106353

Smilagenin 1 Publications Verification	Structural Classification Pelargonium hortorum Bailey Liliaceae Neurological Disease Classification of Application Fields Anemarrhena asphodeloides Bunge Plants Disease Research Fields Geraniaceae Steroids	mAChR Endogenous Metabolite
Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .

HY-155535

17β-HSD10-IN-2	Structural Classification Monophenols Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor，targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10)，a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer .

HY-N0222

Avicularin 3 Publications Verification	Flavonols Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Disease Research Fields Inflammation/Immunology Lindera aggregata (Sims) Kosterm.	COX NF-κB PPAR ERK GLUT Apoptosis
Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities .

HY-N0749

Jatrorrhizine	Alkaloids Monophenols other families Source classification Phenols Plants Isoquinoline Alkaloids	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0740

Jatrorrhizine chloride	Alkaloids Monophenols Source classification Ranunculaceae Coptis chinensis Franch. Phenols Plants Isoquinoline Alkaloids	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0749A

Jatrorrhizine hydroxide	Alkaloids Monophenols Source classification Ranunculaceae Coptis chinensis Franch. Phenols Plants Isoquinoline Alkaloids	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-16569

Colchicine Maximum Cited Publications 29 Publications Verification	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Disease Research Fields Cancer	Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC₅₀ of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .

Cat. No.	Product Name	Chemical Structure

HY-18260S1

Bisphenol A-d6

Bisphenol A-d₆ is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].

HY-18260S

Bisphenol A-d16

Bisphenol A-d₁₆ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S4

Bisphenol A-d4

Bisphenol A-d₄ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-18260S6

Bisphenol A-d14

Bisphenol A-d₁₄ is a deuterium labeled Bisphenol A (HY-18260). Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-18260S3

Bisphenol A-d8

Bisphenol A-d₈ is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].

HY-18260S5

Bisphenol A-d4-1

Bisphenol A-d₄-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

HY-113354S

Anserine-d4

Anserine-d₄ is the deuterium labeled Anserine. Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice[1][2].

HY-113354S1

Anserine-d4 hydrochloride

Anserine-d₄ hydrochloride is the deuterium labeled Anserine (HY-113354). Anserine, a methylated form of Carnosine, is an orally active, natural Histidine-containing dipeptide found in skeletal muscle of vertebrates. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice .

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

HY-B0976AS

Fenoterol-d6 hydrobromide
Fenoterol-d₆ (hydrobromide) (Th-1165a-d6) is the deuterium labeled Fenoterol hydrobromide. Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks